Following the apparent elimination of a late-stage gene therapy study last week, Swiss drug juggernaut Roche has confirmed that it’s axing a hemophilia candidate inherited in its 2019 buyout of Spark ...
On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON Phase 1/2 trial of BEAM-101, an investigational genetically modified cell ...
Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard concurrent ...
BOOST Pharma ApS, a clinical-stage biopharmaceutical company focused on developing novel cell therapies for rare skeletal pediatric diseases, today announced that Sound Bioventures has joined its ...
Dr. Joshua Reuss joints that podcast to discuss the latest changes to the living guideline on stage IV NSCLC with driver alterations. He discusses the new evidence for NSCLC with EGFR mutations and ...
HONG KONG, Aug. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study ...
One of the top fundraisers of 2024 is halving its workforce about a year after drawing in a $325 million series C. Cell therapy biotech Arsenal Biosciences has laid off about 50% of its staff as it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback